N-<(phenylmethoxy)carbonyl>-4(S)-methoxy-(S)-proline methyl ester | 75176-19-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-<(phenylmethoxy)carbonyl>-4(S)-methoxy-(S)-proline methyl ester
• 英文别名: methyl (2S,4S)-1-benzyloxycarbonyl-4-methoxypyrrolidine-2-carboxylate；(1-benzyloxycarbonyl-(4S)-methoxy-(2S)-pyrrolidinyl)carboxylic acid methyl ester；(4S)-methoxy-(2S)-proline methyl ester-1-carboxylic acid benzyl ester；N-carbobenzyloxy-4-cis-methoxy L-proline methyl ester；phenylmethyl (S)-4-methoxy-(S)-2-(methoxycarbonyl)-pyrrolidine carboxylate；(2S,4S)-1-benzyl 2-methyl 4-methoxypyrrolidine-1,2-dicarboxylate；1-O-benzyl 2-O-methyl (2S,4S)-4-methoxypyrrolidine-1,2-dicarboxylate
• CAS: 75176-19-1
• 化学式: C₁₅H₁₉NO₅
• 分子量: 293.32
• InChiKey: GRYKIXJYTLTYIF-STQMWFEESA-N

物化性质

• 沸点：
  398.7±42.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  65.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-<(phenylmethoxy)carbonyl>-4(S)-methoxy-(S)-proline methyl ester 在 氢溴酸 、 溶剂黄146 作用下， 以 吡啶 为溶剂， 反应 20.0h， 生成 (2S,4S)-1-(3-Acetylsulfanyl-2-methyl-propionyl)-4-methoxy-pyrrolidine-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Synthesis and pharmacological activity of angiotensin-converting enzyme inhibitors: N-(mercaptoacyl)-4-substituted-(S)-prolines

  摘要：

  The synthesis of a series of N-(mercaptoacyl)-4-substituted-(S)-prolines (2 and 3) is described. These compounds were evaluated in vitro for inhibition of angiotensin-converting enzyme (ACE), and selected compounds were evaluated in vivo for ACE inhibition. The most potent compounds in vitro are 108, 109, 111, 114, and 116, having relative potencies of 1.0, 1.0, 1.3, 1.1, and 2.6 as compared to the potency of captopril. The most potent compounds in vivo intravenously are 108, 111, 114, 116, 117, and 97.

  DOI：

  10.1021/jm00399a033
• 作为产物：
  描述：

  (2S,4S)-1-(苄基羰基)-4-羟基吡咯烷-2-羧酸 在 氯化亚砜 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 23.0h， 生成 N-<(phenylmethoxy)carbonyl>-4(S)-methoxy-(S)-proline methyl ester
  参考文献：
  名称：

  Synthesis and pharmacological activity of angiotensin-converting enzyme inhibitors: N-(mercaptoacyl)-4-substituted-(S)-prolines

  摘要：

  The synthesis of a series of N-(mercaptoacyl)-4-substituted-(S)-prolines (2 and 3) is described. These compounds were evaluated in vitro for inhibition of angiotensin-converting enzyme (ACE), and selected compounds were evaluated in vivo for ACE inhibition. The most potent compounds in vitro are 108, 109, 111, 114, and 116, having relative potencies of 1.0, 1.0, 1.3, 1.1, and 2.6 as compared to the potency of captopril. The most potent compounds in vivo intravenously are 108, 111, 114, 116, 117, and 97.

  DOI：

  10.1021/jm00399a033

文献信息

• VLA-4 INHIBITOR
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1757602A1

  公开（公告）日：2007-02-28

  An object of the present invention is to provide a compound which selectively inhibits binding of a ligand and α4β1 integrin (VLA-4), a process for producing the compound, and a medicament containing the compound. A compound represented by the formula (I) etc. orasaltthereof, a process for producing the compound or a salt thereof, a medicament containing the compound or a salt thereof, as well as a preventive and/or a therapeutic agent for a disease caused by cell adhesion, for example, inflammatory reaction, autoimmune disease, cancer metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease and rejection reaction at transplantation, containing the compound or a salt thereof as a primary component. [wherein Y1 represents a divalent aryl group etc. , V1 represents an aryl group etc., and R11 to R14 represent H, OH or a halogen atom etc.]

  本发明的一个目的是提供一种化合物，该化合物选择性地抑制配体与α4β1整合素（VLA-4）的结合，以及包含该化合物的药物的制备过程。化合物的结构如公式（I）所示，或其盐，制备该化合物或其盐的过程，包含该化合物或其盐的药物，以及作为细胞粘附引起的疾病（例如炎症反应、自身免疫疾病、癌症转移、支气管哮喘、鼻阻塞、糖尿病、关节炎、银屑病、多发性硬化症、炎症性肠病和移植排斥反应等）的预防和/或治疗剂，包含该化合物或其盐作为主要成分。【其中Y1代表双价芳基等，V1代表芳基等，R11至R14代表H、OH或卤素原子等】
• [EN] VLA-4 INHIBITOR<br/>[FR] INHIBITEUR DE VLA-4
  申请人：DAIICHI SEIYAKU CO

  公开号：WO2005121135A1

  公开（公告）日：2005-12-22

  A compound which selectively inhibits bonding between a ligand and α4β1 integrin (VLA-4); a process for producing the compound; and a medicine containing the compound. The compound is one represented by, e.g., the formula (I) or a salt thereof. Also provided is a preventive and/or therapeutic agent which contains the compound or salt as a major component and is effective against diseases attributable to cell adhesion, such as, e.g., inflammatory reaction, autoimmune disease, cancer metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory intestinal disease, and rejection reaction in transplantation. (In the formula, Y1 represents arylene, etc.; V1 represents aryl, etc.; and R11 to R14 each represents H, OH, halogeno, etc.)

  一种选择性抑制配体与α4β1整合素（VLA-4）结合的化合物；一种生产该化合物的方法；以及含有该化合物的药物。该化合物可由例如式（I）或其盐所代表。还提供了一种预防和/或治疗剂，其含有该化合物或盐作为主要成分，并对由细胞粘附引起的疾病具有有效性，例如炎症反应、自身免疫疾病、癌症转移、支气管哮喘、鼻塞、糖尿病、关节炎、牛皮癣、多发性硬化、炎症性肠道疾病和移植排斥反应等（在该式中，Y1代表芳基等；V1代表芳基等；R11至R14分别代表H、OH、卤素等）。
• Angiotensin II antagonists
  申请人：Eli Lilly and Company

  公开号：US05612360A1

  公开（公告）日：1997-03-18

  This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.

  这项发明提供了新颖的杂环衍生物，它们的制药配方，以及它们用于拮抗哺乳动物中的血管紧张素II受体的用途。
• TRIAZINE KINASE INHIBITORS
  申请人：Velaparthi Upender

  公开号：US20100197654A1

  公开（公告）日：2010-08-05

  The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents.

  该发明提供了公式I的化合物及其药用盐。公式I的化合物抑制酪氨酸激酶活性，因此它们可用作抗癌药物。
• Angiotensin II antagonist intermediates
  申请人：Eli Lilly and Company

  公开号：US05556981A1

  公开（公告）日：1996-09-17

  This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.

  该发明提供了新颖的杂环衍生物，它们的药物配方以及它们用于拮抗哺乳动物中的血管紧张素II受体的用途。